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Abstract
The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) alleviate symptoms of experimental neuropathy,
protect and stimulate regeneration of sensory neurons in animal models of neuropathic pain, and restore their functional
activity. However, clinical development of GFL proteins is complicated by their poor pharmacokinetic properties and
multiple effects mediated by several receptors. Previously, we have identified a small molecule that selectively activates
the major signal transduction unit of the GFL receptor complex, receptor tyrosine kinase RET, as an alternative to GFLs, for
the treatment of neuropathic pain. We then introduced a series of chemical changes to improve the biological activity of
these compounds and tested an optimized compound named BT44 in a panel of biological assays. BT44 efficiently and
selectively stimulated the GFL receptor RET and activated the intracellular mitogene-activated protein kinase/extracellular
signal-regulated kinase pathway in immortalized cells. In cultured sensory neurons, BT44 stimulated neurite outgrowth with
an efficacy comparable to that of GFLs. BT44 alleviated mechanical hypersensitivity in surgery- and diabetes-induced rat
models of neuropathic pain. In addition, BT44 normalized, to a certain degree, the expression of nociception-related
neuronal markers which were altered by spinal nerve ligation, the neuropathy model used in this study. Our results suggest
that the GFL mimetic BT44 is a promising new lead for the development of novel disease-modifying agents for the treatment
of neuropathy and neuropathic pain.
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Introduction
Lesions or diseases of the somatosensory system may
cause chronic neuropathic pain1 which impairs the
patient’s quality of life and causes a challenge to the
health-care system.2,3 Neuropathic pain affects millions
of people worldwide, occurring more often in the elderly.
It is difficult to treat, and it is often underdiagnosed and
undertreated.4 It can be caused, for example, by injuries,
cancer, infections (Herpes Zoster, HIV), and metabolic
diseases such as diabetes.5–9 Existing pain therapies con-
trol neuropathic pain only in a minority of patients, and
they may cause significant side effects.10 Importantly,
they fail to normalize the underlying changes in the
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nervous system. Thus, there is an urgent need for the
development of new medications.
The proteins supporting and regenerating neurons
such as the glial cell line-derived neurotrophic factor
(GDNF) family ligands (GFLs) artemin (ARTN) and
GDNF are among the interesting targets for neuropathic
pain therapy. These proteins attenuate the signs of neu-
ropathy and stimulate the regeneration of sensory neu-
rons in experimental animals.11–15 However, ARTN and
GDNF have poor pharmacokinetic properties, and their
transition to clinical use is challenging.16,17 Besides, they
are expensive to produce, and it is difficult to maintain a
uniform biological activity among batches.
GFLs signal predominantly via a receptor complex
consisting of a signal transduction module represented
by a receptor tyrosine kinase called RET and a ligand-
binding subunit—GDNF family receptor alpha 1–4
(GFRa1-4), which provides binding specificity. Sensory
neurons mostly express RET, GFRa1 (the preferred
co-receptor for GDNF), and GFRa3 (the preferred
co-receptor for ARTN). A few sensory neurons are
also positive for GFRa2, which primarily binds another
GFL called neurturin (NRTN). The expression of
GFRa2, however, is downregulated upon nerve injury
and therefore, NRTN administration is considered to be
of little significance in NP therapy. In addition to RET,
GFLs can also transmit the signal via other receptors
such as the neural cell adhesion molecule (NCAM)18
or syndecan-3.16 GFLs are important for the develop-
ment and maintenance of nociceptive neurons,19 and
they have induced thermal hypersensitivity in both
experimental animals20 and patients.21,22 However, at
least some of the effects of GFLs on temperature per-
ception (e.g., cold pain) might be mediated by other
receptors than RET.20
Small molecules with improved pharmacological
characteristics selectively activating GFL-like signaling
via RET could be a good alternative for clinical use. The
first of these candidates, XIB4035, considered a small-
molecule agonist for GFRa1, activated RET in mouse
neuroblastoma cell line cells23 and alleviated experimen-
tal diabetic neuropathy in rodents. However, it was later
shown to increase the activity of GDNF or ARTN
rather than to directly activate GFL receptors,24 which
limits its therapeutic applications.
Previously, we have identified the first chemical com-
pounds BT1325,26 and BT1827,28 which selectively acti-
vate RET and its downstream targets in the absence of
GFLs and support sensory neurons.
Recently, we developed a third-generation GFL
mimetic BT44 with predicted improved properties
using computational chemistry methods. In this study,
we tested the biological activity of BT44 focusing on the
sensory system. We first proved that BT44 selectively
activates RET, but has no effect on TrkA and TrkB
receptors. We further studied whether BT44 supports
sensory neurons in vitro and alleviates behavioral man-
ifestations of experimental neuropathy in vivo, using two
animal models: spinal nerve ligation (SNL) and strepto-
zotocin (STZ)-induced diabetes mellitus (DM) (a model
of type 1 diabetes). These models were chosen because
the activation of GFL/GFRa/RET signaling in these NP
models was shown to produce positive effects. We also
assessed the ability of BT44 to restore damaged dorsal
root ganglion (DRG) neurons in vivo.
Material and methods
Proteins
ARTN and GDNF were purchased from PeproTech
(USA).
The design and synthesis of BT44
Earlier, we described the discovery of the first direct
RET agonist that supports sensory neurons in vitro
and in vivo and alleviates surgery-induced neuropathy
in experimental animals in high throughput screening.25
To improve its biological activity, we first developed
fragmental quantitative structure-activity relationship
(FQSAR) models using known crystal structures of the
GFRa1 and GFRa3 co-receptors,29,30 the previously
described compound XIB403523 which is able to modu-
late the biological activity of GFLs24 and related small
molecules with demonstrated activity towards RET.
Compounds were docked to the GFRa3 using the
Autodock 3.0 program.31 Grid maps of 120 120 120
grid points at a spacing of 0.375 A˚ were generated
around the center of the ligand binding site by the
Autogrid program. Kollman’s partial charges were
used for heavy atoms and polar H atoms of the protein.
Atomic solvation parameters and fragmental volumes
were obtained from the Addsol program. Gasteiger
charges were assigned to the ligand molecules. The pre-
dicted free energies of binding of the ligands to the pro-
teins were calculated by using the scoring functions
implemented in the program package AutoDock.
Thereafter, FQSAR models were developed for the pre-
dicted binding free energies of the compounds as
described elsewhere.32 Several ligands with predicted
low free binding energies to both co-receptors were
found, including compound BT44 were designed. BT44
was synthesized by EvoBlocks (Hungary) with the purity
of 98.6% (LCMS).
The structure, integrity, and purity of the resulting
compound was confirmed in NMR experiments
recorded on a Bruker Avance III HD NMR spectrom-
eter operated at 1H frequency of 850.4MHz equipped
with a cryogenic probe head by NMR facility at the
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(Supplemental Material).
Luciferase assay
Luciferase assay was performed as described previous-
ly.33 MG87RET murine fibroblasts34 stably transfected
with PathDetect-Elk1 (Stratagene, USA) and one of the
following GFRa1-, GFRa3-expressing plasmids, or
pcDNA6 vector33 were plated onto 96-well plates with
a density of 20,000 cells/well in DMEM, 10% FBS,
100 mg/ml NormocinTM (Invivogen, USA), 1% DMSO,
15mM HEPES pH 7.2 the day before the assay. The
next day, BT44 was applied to cells in concentrations
of 0.1, 1, 5, 10, 25, and 50 lM in DMEM, 15mM
HEPES, 1% DMSO. ARTN and GDNF (100 ng/ml)
were used as positive controls for GFRa3/RET and
GFRa1/RET-expressing cells, respectively. The follow-
ing day, media was discarded and 30 ml of NeoLite
reagent (Perkin Elmer) diluted 1:1 with PBS was added
to the wells. The plate was incubated on the shaker (RT)
for 10min, and luminescence was measured using
Victor3 1420 multilabel counter (Perkin Elmer/Wallac).
Measurements were done in quadruplicates and the bio-
logical activity of the compounds was evaluated in four
independent experiments.
Phosphorylation assays
Phosphorylation assays were performed as described
previously.35 Phosphorylation of receptor tyrosine
kinase RET in cultured cells was assessed by antibodies
against phosphorylated tyrosine residues (clone 4G10,
Merck Millipore) after immunoprecipitation of RET
with RET specific antibodies C-20 (sc-1290, Santa-
Cruz Biotechnology Inc., USA). Phosphorylation of
Trk receptors was analyzed after immunoprecipitation
of Trk with the anti-pan Trk antibody C-14 (sc-11,
Santa-Cruz Biotechnology Inc., USA).
Phosphorylation of the intracellular signaling protein
ERK was determined using specific antibodies against
phosphorylated forms of the respective proteins in
whole cell lysates (see below). MG87RET, MG87TrkA
or MG87TrkB cells were plated onto six-well plates a
day before the experiment. MG87RET cells were trans-
fected with 4mg/well of GFRa3- or GFP- expressing
plasmid using Turbofect (Thermo Fisher Scientific).
Before the stimulation with the compounds, cells were
starved for 4 h in serum-free DMEM supplemented with
1% DSMO, 15mM Hepes pH 7.2 and stimulated with
7.5, 18, 35, or 75 lM BT44 for 15min. 100 ng/ml ARTN
(250 ng/ml), NGF (200 ng/ml), or BDNF (200 ng/ml)
were used as positive controls in MG87/RET/GFRa1,
MG87TrkA, and MG87TrkB cells, respectively. After
the stimulation with test compounds, the cells were
washed once with ice-cold PBS containing 1mM
Na3VO4 and 1mM NaF and lysed on ice in 500 ml per
well of RIPA-modified buffer (50mM Tris-HCl, pH 7.4,
150mM NaCl, 1mM EDTA, 1% NP-40, 1% TX-100,
10% glycerol, EDTA-free protease inhibitor cocktail
(Roche), 1mM Na3VO4, 2.5mg/ml of sodium deoxycho-
late, 1mM NaF). Subsequently, 80 ll of the whole cell
lysate was removed, mixed with 80ll of Laemmli load-
ing buffer (4% SDS, 20% glycerol, 10% 2-mercaptoe-
thanol, 0.004% bromophenol blue, 0.125M tris-HCL
pH 6.8) and boiled for 10min to prepare the samples
for the analysis of pERK levels. The remaining lysates
were centrifuged for 10min (10,600g, 4C, Eppendorf
table-top centrifuge) to precipitate cell debris.
Supernatants were collected and incubated with 2mg/
ml of RET C-20 antibodies (sc-1290, Santa-Cruz
Biotechnology Inc., USA) or 2 mg/ml of Trk C-14 anti-
bodies and Dynabeads Protein G magnetic beads
(Thermo Fisher Scientific) overnight onto a rotator at
þ4C to immunoprecipitate RET. The following day,
the beads were separated from the lysate by using a mag-
netic holder, washed twice with 1xTBS containing 1%
TX-100, mixed with 50 ll of Laemmli loading buffer,
boiled for 5min and centrifuged at 17,900g for 5min.
The whole cell lysate samples were resolved on 12%
sodium dodecyl sulphate-polyacrylamide gel electropho-
resis (SDS-PAGE), and proteins, immunoprecipitated
by RET or Trk antibodies—on 7.5% SDS-PAGE. The
samples were then transferred to a nitrocellulose mem-
brane (GE Healthcare).
Membranes were blocked in TBST-T with 10%
skimmed milk for 10min. The membranes were probed
with pERK (1:500, E4, Santa-Cruz Biotechnology, Inc)
or phospho-tyrosine (pY) (1:1000, clone 4G10, Cat N
05–321, Merck Millipore) antibodies in 3% milk in
TBS-T overnight at þ4C. The membranes were
washed three times for 10min with TBS-T and incubated
in a solution of a secondary antibody conjugated with
horse radish peroxidase in TBS-T (1:3000, anti-mouse,
Dako) for 1 h at room temperature. The membranes
were washed with TBS-T three times for 15min.
Stained bands were visualized with an ECL reagent
(Pierce) using Luminescent Image Analyzer LAS3000
(Fuji-Film). To confirm equal loading, the membranes
were stripped and re-probed with anti-RET C-20 (1:500,
SantaCruz Biotechnology Inc), anti-Trk C-14 (1:1000,
SantaCruz Biotechnology Inc), or anti-GAPDH
(1:4000, Millipore) antibodies using a similar protocol
to those described above.
Westren blots were quantified using Image Studio 5.2
software (LI-COR Biosciences). Intensities of the bands
of the phosphorylated form of RET (MW¼ 170 kDa)
and pERK were normalized to the band intensities of
RET and GAPDH respectively. Furthermore, values for
pRET/RET ratios and pERK/GAPDH ratios in vehicle
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and compound treated wells were expressed as percent-
age of activation with the values in ARTN-treated wells
standardized to 100%. The area in which optical density
of each band was measured was of the same size for all
analyzed membranes.
DRG culture and neurite outgrowth assay
The cultures of DRG neurons were prepared as
described by Paveliev et al.36 with small modifications.
DRGs were dissected from the spine of the healthy male
P30 Wistar rats purchased from The Laboratory Animal
Centre of the University of Helsinki. The permission to
use experimental animals for research purposes
(KEK14-019) was given by The Laboratory Animal
Centre of the University of Helsinki. Ganglia were
cleaned from nerve fibers in PBS and washed two
times with Ca2þ and Mg2þ free HBSS (ThermoFisher
Scientific). The ganglia were incubated in HBSS contain-
ing trypsin (5mg/ml) and collagenase/dispase (10mg/ml)
for 30 to 60min at 37C, washed once with HBSS-
DNase I solution, and triturated in HBSS-DNAase I
solution until disappearance of visible tissue pieces.
Supernatants were transferred to the fresh tube, the
cells were precipitated by centrifugation at 110 g for
5min, washed two times with neuron culturing media
(1xNeurobasal medium, 1xB-27, 100 mg/ml primocin,
25 lM L-glutamine, 0.1% DMSO) and plated on poly-
ornithine and laminin-precoated coverslips. Neurons
were cultured in the presence of 0.5–10 mM BT44 or
ARTN (30 ng/ml) for a positive control for 16–20 h.
Afterwards, the DRG neurons were fixed with 4%
PFA for 10min at RT, washed with PBS, and permea-
bilized with 1xPBS containing 0.1% Triton X-100
(PBS-T). DRG neurons were probed with 1:500 rabbit
anti-PGP9.5 antibodies (Enzo Biochem Inc., USA) and
visualized with anti-rabbit secondary antibodies conju-
gated with Alexa488 1:200 (Invitrogen). Mounting was
done with Imu-mount (Thermo Scientific). The number
of PGP9.5-positive neurons with neurites at least twice
as long as the body was quantified under fluorescent
microscope (Zeiss5) and normalized to the total
number of neurons. The counting in random vision
fields on coverslips was carried out by the observer
who was blinded to the treatment groups. Experiments
were performed at least in triplicates and each concen-
tration of BT44 was evaluated in four to five indepen-
dent experiments. At least 70 neurons per treatment
group were analyzed in each experiment. For the statis-
tical analysis, the data for technical replicates were aver-
aged. For representation purposes, the data were
converted to percentages from the values in vehicle-
treated wells for each experiment and the results for all
concentrations were pooled together.
Experimental animals
Neuropathy was induced by SNL and STZ-induced dia-
betes. The experiments were performed in male Wistar
rats (Envigo Laboratories, Horst, Netherlands). The rats
weighed 150 g (SNL) and 200–250 g (STZ and controls)
at the beginning of the experiments.
The animals were housed in groups of two to four in
plastic cages with a layer of saw dust in ambient temper-
ature (22–24C) and artificial lighting with a fixed 12-h
light–dark cycle. Pellet food and tap water were avail-
able ad libitum. The experiments were performed in
accordance to the 3R principles and all efforts were
made to limit distress for the animals. The experiments
were performed using the minimum number of animals
necessary to produce reliable scientific data. The animals
were habituated to handling and to the experimental
conditions for two to three consequent days before the
experiments. The animals were again habituated to test
settings for 15min before the actual measurements. The
Experimental Animal Ethics Committee of the
Provincial Government of Southern Finland (Etel€a-
Suomen aluehallintovirasto, H€ameenlinna, Finland;
Permission # ESAVI/7929/04.10.07/2014) had approved
the methods and the experiments were performed
according to the guidelines of the European Parliament
and the Council Directive of 22 September 2010 (010/63/
EU), International Association for the Study of Pain,37
and the ARRIVE guidelines.38–40
After surgery, the SNL animals were observed by an
experienced researcher on daily basis to detect any com-
plications of surgery or motor complications produced
by unintended damage of L4 spinal nerve, loss of weight,
or any other abnormal signs. Similarly, the STZ-treated
animals were monitored on daily basis throughout the
experiment to detect weight loss of more than 20% or
any signs of suffering in behavior. No complications
were observed.
Techniques for producing the SNL model of peripheral
neuropathy
Unilateral ligation of two spinal nerves (L5 and L6) was
performed under isoflurane anesthesia (Baxter Oy,
Helsinki, Finland, diluted in air, 4.5% for induction
and 2%–3% for maintenance) as described in detail ear-
lier.41 The left L5 and L6 spinal nerves were exposed by
removing a small piece of the paravertebral muscle and
part of the left spinous process of the L5 lumbar verte-
bra. The L5 and L6 spinal nerves were carefully isolated
from the L4 spinal nerve and other surrounding tissues
and tightly ligated with 6–0 silk (Perma-Hand Seide,
Ethicon, Belgium). After ligation, the muscle and the
adjacent fascia were closed with sutures (Vicryl-Rapid
3/0, Ethicon, Belgium) and the skin with metal clips.
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In the SNL experiments, only animals developing
hypersensitivity to mechanical stimulation with digital
von Frey test before treatments and with no motor
impairment were included in the study.
Animal model of DM
The STZ-induced model of DM is associated with hyper-
sensitivity to various types of pain stimuli.42 DM was
induced in a group of animals by intraperitoneal injec-
tion of STZ (60mg/kg; Sigma-Aldrich, St. Louis, MO,
USA) in citrate buffer (pH 4.5). The blood glucose levels
in the experimental animals were measured first after
overnight fasting before the injection of STZ or vehicle
and at the end of the experiment using Accu Chek Aviva
(Roche, Basel, Switzerland). Non-fasting blood glucose
levels were measured at regular intervals during the
experiment. STZ-treated animals which had a non-
fasting blood glucose level of 20mmol/l the day after
the STZ injection were excluded from the study.
Consequently, four STZ-treated animals were excluded
from the study.
To study any possible long-term effects of BT44 on
DM, glycosylation of hemoglobin (HbA1C) levels were
measured from the whole blood samples at the end of
the experiment with Siemens DCA 2000þ system.
Treatments
The SNL animals received 1, 5, 12.5, or 25mg/kg of
BT44 in two independent experiments. In the first exper-
iment (Figure 5(a)), animals received 12.5 or 25mg/kg of
BT44 dissolved in corn oil containing 5% DMSO and
injected subcutaneously (s.c.) every second day for
10 days, starting on the second day after the nerve
injury. In the second experiment, SNL animals received
1 or 5mg/kg of BT44. Vehicle groups received corn oil
containing 5% DMSO.
The STZ-treated animals received 5 or 12.5mg/kg of
BT44 in two independent experiments (Figure 6(a)). In
the first experiment assessing the long-term effects of
BT44, the animals received vehicle, 5 or 12.5mg/kg of
BT44 for 42 days. In the second experiment, STZ-treated
animals received vehicle or 5mg/kg of BT44 for 14 days.
BT44 was dissolved in propylene glycol and injected s.c.
every second day, starting on the next day after the injec-
tion of STZ. Vehicle groups received propylene glycol.
The vehicle was also administered to healthy control
animals. For the statistical analysis and representation
purposes, the data from the first and second experiment
were pooled together.
To evaluate the effects of BT44 in healthy control
animals, rats were treated with 5 or 12.5mg/kg of
BT44 dissolved in propylene glycol s.c. every second
day for twoweeks. The vehicle group received propylene
glycol.
In all experiments, the animals were randomly
assigned to the vehicle and BT44 treatment groups and
in the SNL experiments, groups were balanced based on
the mechanical nociceptive thresholds measured two -
days after SNL. Behavioral assessments were made by
an observer who was blinded to the treatment.
Behavioral tests
In the SNL animals, mechanical sensitivity (allodynia)
was assessed using digital von Frey test and cold
allodynia with acetone test before surgery, before the
first BT44 injection and every other day after surgery
(Figure 5(a)). In the SNL animals, behavioral
tests were performed in the ipsilateral and contralateral
sides.
In the STZ-treated animals, mechanical sensitivity
was assessed using digital von Frey test and/or paw
pressure test. Heat and cold sensitivity was assessed
using the Hargreaves plantar test and the acetone
test, respectively. In the first experiment, all tests were
performed before the injection of STZ, before the first
BT44 injection, and one, two, three, four, and sixweeks
after the injection of STZ (Figure 6(a)). In the second
experiment plantar, thermal and cold tests were per-
formed before the injection of STZ, before the first
BT44 injection, and one and twoweeks after the injec-
tion of STZ (Figure 6(a)). In the STZ-treated animals, at
each time point, the tests were performed at 5min
intervals in the same order. The Hargreaves test was
performed first in the left paw, then the digital von
Frey test to the right paw, the acetone test to the left
paw, and finally the paw pressure test was performed to
the right paw.
To assess whether BT44 has any effect in healthy con-
trol rats, we assessed mechanical sensitivity with the paw
pressure test and cold sensitivity with the acetone test in
healthy animals. The nociceptive tests were performed
before the first drug administration and once a week
for two weeks. To assess the acute effect of BT44 admin-
istration, the tests were also performed 1 and 3 h after
the first drug administration.
Before the Hargreaves plantar test, the rats were
placed on a glass plate and before the mechanical
(vonFrey) and cold tests, on a metal mesh covered
with a plastic dome to habituate to the test settings for
15min before the actual measurements.
To measure mechanical sensitivity (mechanical allo-
dynia) in the SNL and STZ-treated animals, we used the
von Frey test in which the plantar surface of the paw was
touched with a metal monofilament (tip diameter
0.5mm) attached to a digital force gauge (Imada
DPS-1, Northbrook, IL, USA). The paw was slowly
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approached and contact was made for 1 s to standardize
the time-course of the stimulation. The force just suffi-
cient to produce a response was applied, and the pres-
sure leading to the reaction was recorded. Brisk foot
withdrawal or lifting and licking of the paw was accept-
ed as a response. At each time point, the threshold was
assessed in triplicates three times at 3min intervals
for each hind paw. In the SNL animals, the measure-
ment was done by alternating between the ipsilateral and
contralateral side. The mean of the three threshold
values at each time point was used in further calcula-
tions. In the STZ-treated animals, the test was per-
formed to the right paw.
To assess heat sensitivity in the STZ-treated animals,
the Hargreaves plantar test (Ugo Basile, Varese, Italy
Comerio, Italy) was performed. The animal was placed
on a glass plate, and radiant heat was applied to the left
hind paw until spontaneous withdrawal of the hind paw
was measured. The time from heat application to with-
drawal was considered as the latency of the withdrawal
response. The cutoff point was set at 10 s after which heat
application was stopped to prevent tissue damage. At
each time point, three latency determinations were per-
formed at 2min intervals. The mean of the three values at
each time point was used in further calculations.
To assess cold sensitivity, the acetone test was per-
formed in the SNL, STZ, and healthy animals. Cold
sensitivity (cold allodynia) was measured as the
number of foot withdrawal responses after application
of cold stimuli to the plantar surface of the paw.43
A drop of acetone was gently applied to the plantar sur-
face of the hind paw with a syringe connected to a thin
polyethylene tube. A withdrawal response of the foot
was considered as a sign of cold allodynia. The test
was repeated five times with an interval of approximate-
ly 2min between each test. In the SNL animals, the
measurements were done by alternating between the ipsi-
lateral and contralateral side, with a 5-min break
between measurements. In the STZ-treated animals,
the acetone test was performed in the left paw.
To assess mechanical sensitivity (mechanical hyperal-
gesia) in the STZ-treated animals and the healthy ani-
mals, the paw pressure test was performed with the Ugo
Basile paw pressure device (Ugo Basile, Varese, Italy
Comerio, Italy). The animals were gently wrapped in a
towel during the test, the right hindpaw was placed
under a pivot and the force applied to the paw was grad-
ually increased. A mechanical force was applied at a rate
of 32 g/s to the hind paw until limb withdrawal or the
cut-off force of 250 g was reached. At each time point,
three threshold determinations were performed at 2min
intervals. The mean of the three threshold values at each
time point was used in further calculations.
Motor performance
To exclude a motor effect of BT44, motor activity of the
STZ-treated animals was assessed with a rotarod test
using the Ugo Basile (Gemonio, Italy) 47700 Rat
RotaRod apparatus, diameter 70mm. The rats were
acclimatized for two consecutive days at a speed of
20 r/min during 60 s. During the testing day (sixth
week), an accelerating speed was used. The starting rota-
tion rate of the rod was 10 r/min, and it was increased to
40 r/min over 60 s. The time the animals were able to stay
on the rod was calculated. The cut off time was 60 s.
Immunohistochemistry
DRGs (L5 for SNL and lumbar for STZ-induced DM)
of the experimental animals were embedded in paraffin,
sectioned for 5 mM sections and probed after deparaffi-
nization with isolectin Griffonia simplicifolia (IB4) con-
jugated with Alexa 488 (1:200; Vector Laboratories,
USA) and antibodies against CGRP (1:10 000,
Peninsula Laboratory, USA). To visualize bound
CGRP primary antibodies, slides were incubated with
biotinylated Goat Anti-Rabbit IgG Antibody (Vector
Laboratories, USA) and ABC-peroxidase conjugate
(VECTASTAIN Elite ABC-Peroxidase Kit antibody,
Vector Laboratories, USA) followed by chromogenic
visualization with DAB staining kit (Vector
Laboratories, USA) according to the manufacturer’s
instructions. In the slides labeled with IB4-Alexa488,
nuclei were stained with DAPI. The slides were mounted
with Immu-Mount (Thermo Scientific, USA) or
Coverquick 2000 (VWR, Finland) and imaged with fluo-
rescent (Zeiss Imager M2 Axio, Carl Zeiss, Germany) or
bright-field (Olympus BX-61, Olympus, Japan) micro-
scopes. The number of marker-positive neurons in a sec-
tion of a DRG was calculated manually and normalized
to the total number of sensory neurons in this section.
The results of the analysis of two to four sections per
ganglion were averaged and used in further calculations.
Determination of drug concentrations in the blood of
healthy animals
To evaluate the concentration of BT44 in the blood, a
separate group of healthy animals was injected s.c. with
a single dose of BT44 (25mg/kg), and venous blood
samples were collected at the 0.5, 1, and 3 h time
points. The blood samples were let to coagulate on ice
after which they were centrifuged at 2000g for 10min at
þ4C. Serum was collected and stored at 80C.
Homogenized serum was mixed with acetonitrile in a
volume ratio of 1:1, and the mixture was vortexed fol-
lowed by centrifugation (16,110g, 5min). The BT44 con-
centration in the supernatants was quantified by Agilent
1100 high performance liquid chromatography (HPLC,
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Agilent Technologies, USA) with a mobile phase com-
posed of Milli-Q water and acetonitrile (volume ratio
40:60) at a flow rate of 1ml/min at 25C. The wavelength
used for the BT44 quantification was 230 nm.
A GeminiVR 3mm NX-C18 110 A˚ column (Phenomenex,
USA) was used as stationary phase and the injection
volume of the samples was 20 lL. This study was con-
ducted in triplicate.
Statistical analysis
Data are presented as mean standard error of the
mean (SEM). Data analysis was performed using
Prism 6.0 software (GraphPad Software, Inc., San
Diego, CA, USA).
All quantitative data were subjected to statistical
analysis. To analyze parametric data (mechanical tests,
Hargreaves plantar test, CGRP-positive neuron counts,
luciferase assay data) significance of the difference
between treatment groups was determined by one or
two-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparison test. Neurite outgrowth
data were analyzed by repeated measures (RM)
ANOVA followed by Dunnett’s multiple comparison
test.44,45 Comparisons between two groups were
performed with two-tailed Student’s t test. P< 0.05
was considered to represent a significant difference.
To analyze non-parametric data (acetone test results,
IB4-positive neuron counts), we used the Mann–
Whitney U test. To analyze the effect of the chronic
treatment of BT44 (acetone test results), the area under
the time–effect curve (AUC) after beginning of the treat-
ment was calculated using the trapezoidal rule. For each
animal, the acetone test results were normalized to the
values on the day when the BT44 injections started
(day 0), subtracting the day 0 value from the response
value of each experiment day. AUCs were calculated
individually for each animal. Significance of the
difference between treatment groups was determined
by Kruskal–Wallis test with Dunn’s multiple compari-
son test.
Results
In vitro biological activity of BT44
BT44 promotes RET phosphorylation and selectively activates
downstream cascades in the cells expressing GFL receptors.
At first, we tested the ability of BT44 (Figure 1(a)) to
activate the luciferase reporter gene controlled by the
(a) (b)
(c) (d)
Figure 1. Chemical structure of BT44 (a) and its ability to activate luciferase reporter in the cells expressing GFRa1/RET (b), GFRa3/RET
(c), and RET (d). Data represent mean SEM. ***P< 0.001, ****P< 0 .0001 (RM one-way ANOVA with Dunnett’s multiple comparison
test: reference corresponding vehicle group); n¼ 4. VEH: vehicle; LCPS: luminescence counts per second.
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MAPK-signaling cascade in the cells expressing recep-
tors for GDNF (GFRa1/RET), ARTN (GFRa3/RET)
and RET alone in four independent experiments. BT44
increased luciferase activity in the reporter cells express-
ing GFRa1/RET (F6,18¼ 19.85, P< 0.0001; Figure 1(b))
and GFRa3/RET (F6,18¼ 13.87, P< 0.0001; Figure 1
(c)), but not in the cells expressing RET alone (Figure
1(d)). In GFRa1/RET expressing cells, 10–50mM of
BT44 increased the activity of luciferase reporter by
approximately two fold (P< 0.0001, Dunnett’s multiple
comparison test). In the GFRa3/RET expressing cells,
5–50 mM of BT44 increased the activity of luciferase
reporter by 1.6–1.9 fold (P< 0.001, Dunnett’s multiple
comparison test). It is important to note here, that all
three reporter cell lines responded to the respective pos-
itive controls as expected, but the RET-expressing cells
were the least responsive. Thus, GDNF (200 ng/ml)
increased luciferase activity in GFRa1/RET-expressing
reporter cells by 59 fold; ARTN (200 ng/ml) in GFRa3/
RET-expressing reporter cells by 37 fold, and the
complex of soluble GFRa1 and GDNF (200 ng/ml) in
RET-expressing reporter cells by only seven fold.
Therefore, lack of luciferase activation by BT44 in the
last cell line could be attributed to its low responsivity to
stimulation in general.
We further tested the ability of BT44 to stimulate
phosphorylation of the RET receptor and the down-
stream ERK signaling cascade using Western blotting
with antibodies specific to the phosphorylated forms
of the above-indicated proteins. We observed an
increase in RET phosphorylation in GFRa3-transfected
MG87RET cells (Figure 2(a) and (e)). In addition, BT44
was also able to activate RET in the absence of co-
receptor (Figure 2(a) and (f)). RM ANOVA revealed
statistically significant differences between the treat-
ments in GFRa3/RET (F4,8¼ 45.86;, P< 0.0001) and
GFP/RET (F4,8¼ 6.781, P¼ 0.0110) expressing cells.
The level of RET phosphorylation increased in GFRa3
and RET-expressing cells treated with BT44 in concen-
trations of 7.5mM by 1.5 fold (P¼ 0.009), 18 mM by
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Figure 2. Selective phosphorylation of RET and activation of downstream signaling in RET-expressing cells by BT44. BT44 increased the
level of phosphorylated RET (a) and ERK (c) in MG87RET cells transfected with GFRa3- or GFP-expressing plasmid. BT44 did not increase
the level of phosphorylated TrkA or TrkB (b) or ERK (d) in MG87TrkA and MG87TrkB cells. Western blot quantification of RET
phosphorylation level (e and f) and ERK phosphorylation levels (g and h). The data are presented as percentages of activation SEM, with
the values in ARTN-treated well standardized to 100%, n¼ 3–7 (e to h). All cell lines respond to respective controls (MG87RET/GFRa3 to
ARTN (250 ng/ml), MG87TrkA to NGF (200 ng/ml) and MG87TrkB to BDNF (200 ng/ml). IP: immunoprecipitation; WB: Western blotting;
NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; pY: phosphotyrosine; pERK: phosphorylated form of ERK1/2;
GAPDH: glyceraldehyde 3-phosphate dehydrogenase, house-keeping protein, loading control; GFP: green fluorescent protein. *P< 0.05,
**P< 0.01, ***P< 0.001, ***P< 0.0001, RM ANOVA with Dunnett’s post hoc test.
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2 fold (P< 0.0001), 35 mM by 2.2 fold (P< 0.0001), and
75 mM by 2.1 fold (P< 0.0001). Similarly, the level of
RET phosphorylation in GFP-expressing cells when
treated with 18 mM of BT44 increased by 2.7 fold
(P¼ 0.0236), 35 mM by 3.2 fold (P¼ 0.0064), and
75 mM by 3.1 fold (P¼ 0.0073, one-way ANOVA with
Dunnett’s post hoc test for all comparisons) (Figure 2(e)
and (f)). We also evaluated the ability of BT44 to acti-
vate ERK, the downstream target of RET. BT44 in con-
centrations of 7.5–75 mM increased phosphorylation
of ERK in both GFRa3/RET and GFP/RET cells
(Figure 2(c), (g), and (h)). RM ANOVA of ERK activa-
tion also revealed statistically significant differences
between the treatments in GFRa3/RET (F4,24¼ 6.038,
P¼ 0.016) and GFP/RET (F4,24¼ 3.781, P¼ 0.0160)
expressing cells. The level of ERK activation increased
in GFR3 and RET-expressing cells treated with BT44 in
concentrations of 7.5 mM by 1.6 fold (P¼ 0.0388), 18 mM
by 1.7 fold (P¼ 0.0259), 35 mM by 1.9 fold (P¼ 0.0037),
and 75 mM by 2 fold (P¼ 0.0004) (Figure 2(c) and (g)).
Similarly, the level of ERK activation in GFP expressing
cells treated with BT44 in concentrations of 35 mM
increased by 2.2 (P¼ 0.0107), and 75 mM by 2.3 fold
(P¼ 0.0098, one-way ANOVA with Dunnett’s post hoc
test for all comparisons), respectively (Figure 2(c) and
(h)). We also evaluated the specificity of the compound
analyzing phosphorylation of the receptor tyrosine kin-
ases TrkA and TrkB transmitting signals from nerve
growth factor (NGF) and brain-derived neurotrophic
factor (BDNF), respectively. BT44 failed to activate
TrkA, TrkB, or ERK in MG87TrkA and MG87TrkB
cells (Figure 2(b) and (d)).
Based on the data collected in experiments performed
in MG87TrkA, MG87TrkB, MG87RET/GFRa3, and
MG87RET/GFP cells, we concluded that BT44 is able
to stimulate RET and RET downstream signaling and
that GFRa co-receptors are dispensable for this process,
although the compound seemed to have some degree of
preference to GFRa3/RET expressing cells in both
reporter gene-based assay (Figure 1) and direct phos-
phorylation assays (Figure 2). Additionally, the com-
pound is selective to RET. Interestingly, BT44 was
able to promote RET phosphorylation in the absence
of GFRa3 co-receptor, but it was unable to activate
luciferase production in the cells lacking GFRa3
(Figure 1). Higher concentrations of BT44 were neces-
sary to statistically significantly increase pRET and
pERK levels in MG87RET cells lacking GFRa3. This
together with low level of luciferase activation also by
positive control proteins in that particular batch of
reporter gene-expressing cells can explain the discrepan-
cy in the results presented in Figures 1 and 2.
BT44 promotes neurite outgrowth from sensory neurons. To
evaluate the effect of BT44 in sensory neurons, we
treated P30 DRG neurons with different concentrations
of this RET agonist. As a positive control we used 30 ng/
ml of ARTN. In the first set of five independent experi-
ments, we compared the neurite-outgrowth promoting
properties of 0.5–5 mM BT44, ARTN, and vehicle. RM
ANOVA showed a significant effect of treatment
(F4,16¼ 8.05, P¼ 0.0009). Dunnett’s post hoc multiple
comparison test revealed that 5 mM BT44 and ARTN
(30 ng/ml) increased the proportion of neurite-bearing
DRG neurons in culture (P¼ 0.03 and P¼ 0.0008,
respectively). In the second set of four independent
experiments, we compared the neurite-outgrowth pro-
moting properties of 10 mM BT44, ARTN, and vehicle.
RM ANOVA showed that the treatment had a signifi-
cant effect (F2,6¼ 5.950, P¼ 0.038). Dunnett’s post hoc
multiple comparison test revealed that 10 mM BT44 and
ARTN (30 ng/ml) increased the proportion of neurite-
bearing DRG neurons in culture (P¼ 0.039 and
P¼ 0.047, respectively). Thus, BT44 dose-dependently
stimulated neurite outgrowth from DRG sensory neu-
rons and its efficacy was comparable to that of ARTN
(see pooled data in Figure 3). Limited solubility of the
compound in cell culture media supplemented with 1%
DMSO precluded us from testing higher concentrations
of BT44 in this assay.
In vivo biological activity of BT44
BT44 concentrations in the serum of healthy rats. Single s.c.
injections of BT44 at the dose 25mg/kg significantly
increased the BT44 concentration in the serum of
healthy animals as shown by ANOVA (F4,13¼ 5.366,
P¼ 0.0089; Figure 4(b)). Dunnett’s post hoc multiple
comparison test revealed that the BT44 concentration
increased after 1 h (P¼ 0.0315) and remained elevated
after 3 h (P¼ 0.0060) of administration indicating that
the compound reached systemic circulation after s.c.
administration and remained in the body for several
hours.
BT44 does not change mechanical and cold sensitivity in healthy
rats. In the healthy animals, BT44 at the doses of 5 and
12.5mg/kg did not affect mechanical sensitivity after
acute (Figure 4(c)) or two weeks’ administration
(Figure 4(e)). Similarly, cold sensitivity and AUC of
the cold response–time curve were not affected by the
treatment (Figure 4(d) and (f)).
BT44 alleviates sensory signs in the SNL and STZ models of
neuropathic pain. In the first SNL experiment, rats
received vehicle or BT44 at doses of 12.5 or 25mg/kg.
Animals developed mechanical allodynia during the first
two days following nerve injury (main effect of time:
F6,144¼ 49.88, P< 0.0001, two-way ANOVA). The com-
pound BT44 alleviated mechanical allodynia in the SNL
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animals (main effect of treatment: F2,24¼ 3.57, P< 0.05,
two-way ANOVA). Dunnett’s post hoc multiple com-
parison test revealed a significant anti-allodynic effect
after 12.5mg/kg, but not after 25mg/kg of BT44
(Figure 5(b)). The SNL animals also developed cold allo-
dynia during the first two days following nerve injury
(Mann–Whitney U test, U¼ 74, P< 0.0001), but neither
12.5 nor 25mg/kg of BT44 showed statistically signifi-
cant effects, and the AUCs of the response–time curve,
normalized to day 0 values, did not differ between
groups (Figure 5(c) and (d)).
In the second SNL experiment, the animals developed
mechanical allodynia during the first two days following
nerve injury (main effect of time: F6,144¼ 39.15,
P< 0.0001), but the lowest doses of BT44 (1 or 5mg/
kg) did not alleviate mechanical allodynia (not shown
in the graphs). None of the BT44 doses influenced the
responses of the contralateral (to injury) paws in either
SNL experiment (not shown).
In the first STZ experiment, the STZ-treated animals
received vehicle or BT44 at doses of 5 or 12.5mg/kg for
six weeks. In the second experiment with STZ-treated
animals, rats received vehicle or BT44 at the dose of
5mg/kg for two weeks. Healthy control animals also
received vehicle in both experiments (Figure 6(a)).
STZ induced mechanical hyperalgesia, but not
mechanical allodynia. In the paw pressure test, the
main effects of time and treatment were significant (F6,
332¼ 19.22, P< 0.0001 and F3,332¼ 3.500, P¼ 0.0158,
respectively). The effect varied between the chronic
treatment groups (interaction between time and treat-
ment: F18,332¼ 2.331, P¼ 0.0018). Post hoc analyses
using Dunnett’s multiple comparison test indicated
that vehicle-treated STZ animals developed mechanical
hyperalgesia during the first twoweeks following the
injection of STZ, as shown by a decrease in the paw
pressure test threshold. BT44 treatment with the dose
of 5mg/kg alleviated mechanical hyperalgesia in the
STZ-treated animals, while the 12.5mg/kg dose was
not effective (Figure 6(b)).
There were no signs of mechanical allodynia in the
STZ-treated animals. Although the main effect of treat-
ment in the von Frey test was significant (F3,224¼ 6.134,
P¼ 0.0005), the main effect of time and interaction
between time and treatment were not. Moreover, post
hoc analyses using Dunnett’s multiple comparison test
indicated that mechanical allodynia did not develop
during the first sixweeks following the injection of
STZ (Supplemental Figure 1(a)).
Also the vehicle-treated STZ animals developed cold
allodynia during the first twoweeks following the
induction of STZ, which lasted for six weeks, as
shown by the increase in the number of responses in
the acetone test (Figure 6(c)). Analysis of the AUC of
the response–time curve normalized to day 0 values
showed that the overall effect of the treatment was sig-
nificant during the first two weeks (d0–d14) (Kruskal–
Wallis test, H¼ 24.61, P< 0.0001) and the later period
of observation (d14–42) (Kruskal–Wallis test,
H¼ 24.61, P< 0.0001). Post hoc analyses using
Dunn’s multiple comparison test indicated that BT44
at 5mg/kg attenuated cold allodynia in the STZ-treated
animals during the first two weeks while the effect of
12.5mg/was not significant (Figure 6(d)). In the later
time frame (d14–42), post hoc analyses using Dunn’s
multiple comparison test indicated that the increase in
cold sensitivity was significant in the vehicle-treated
STZ animals but not in the BT44-treated STZ animals
(Figure 6(d)).
Moreover, the main effects of time and treatment
in the Hargreaves plantar test latency were
significant (F6,332¼ 8.518, P< 0.0001 and F3,332¼
8.565, P< 0.0001, respectively). However, the effect
did not vary with the chronic treatment group. The
post hoc analyses using Dunnett’s multiple comparison
test indicated that the healthy control animals were
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Figure 3. Stimulation of neurite outgrowth from sensory neu-
rons by BT44. Dorsal root ganglion neurons were treated with
0.5–10 mM BT44 or ARTN (30 ng/ml) for 16–20 h. (a)
Representative images of PGP9.5-stained DRG neurons. (b) The
mean percentage of the neurons with neurites of at least two
times longer than neuron body was calculated using the data from
four to five independent experiments per concentration. For
representation purposes, the data are expressed as mean SEM
from vehicle-treated well, with the values in vehicle-treated well
standardized to 100%, n¼ 4–5. *P< 0.05, ***P <0.001 (RM one-
way ANOVA from independent experiments with Dunnett’s mul-
tiple comparison test: reference corresponding vehicle group).
VEH: vehicle; ARTN1: ARTN-treated cells in the first set of
experiments; ARTN2: ARTN-treated cells in the second set of
experiments. Scale bar¼ 100mm.
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sensitized to heat. This sensitization was not seen in
any of the STZ-treated animal groups (Supplemental
Figure 1(b)).
BT44 did not influence motor activity of the STZ-
treated animals (Supplemental Figure 2). STZ attenuat-
ed the increase of body weight (F1,18 ¼19.47,
P¼ 0.0003), and this was not affected by BT44 at the
doses of 5 or 12.5mg/kg (Supplemental Figure 3(a)).
Blood glucose and HbA1c levels were increased in the
STZ-treated animals (F1,18 ¼14.51, P¼ 0.0013 and t(9)
¼17.02, P< 0.0001, respectively, Supplemental Figure 3
(b) and (c)). BT44 did not influence the blood glucose
and HbA1c levels of the STZ-treated animals
(Supplemental Figure 3(a) to (c)).
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Figure 4. Acute and chronic effects of BT44 in healthy control rats. Scheme of the experiments (a). In (b), rats received a single injection
of BT44 or vehicle subcutaneously (s.c.). Serum was collected before (BL), 0.5, 1, and 3 h after the injections (dashed lines) (a). In (c) to (f),
rats received BT44 or vehicle s.c. once daily every second day for twoweeks after behavioral tests (black stripes) (a). BT44 at the dose
25mg/kg increased BT44 serum concentration significantly 1 h and 3 h post administration (b). Mechanical sensitivity was assessed with the
paw pressure test (c and e) and cold sensitivity with the acetone test (d and f) in healthy animals which received 5 or 12.5mg/kg of BT44
acutely (c and d) or every second day for twoweeks (e and f). Panels (c) and (e) show thresholds (g) to mechanical stimulation. Panels
(d) and (f) show cold sensitivity responses to acetone (positive responses/five trials). Data represent mean SEM. *P< 0.05, **P< 0.01,
***P< 0.001 (RM one-way ANOVA with Dunnett’s multiple comparison test: reference corresponding baseline in the healthy controls). n
(c–f)¼ 5–7 and n (b)¼ 2–4. BL: baseline; VEH: vehicle.
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BT44 protects IB4-positive neurons in DRGs of animals with
experimental neuropathy. Sensory neurons in DRGs can
be broadly divided into two classes: peptidergic, which
express the calcitonin-gene related peptide (CGRP) as a
marker and non-peptidergic neurons which express car-
bohydrates binding isolectin B4 (IB4). We analyzed the
levels of expression of these markers in DRGs of SNL
and diabetic animals treated with vehicle or BT44. In
contralateral DRGs of the vehicle-treated rats in the
SNL experiment, 39.8% 0.79% of the neurons
expressed CGRP and 52.5% 0.93% of the neurons
expressed IB4. SNL led to robust reduction in the
number of neurons positive for both of these markers
in ipsilateral DRGs. IB4-positive neurons completely
disappeared from the ipsilateral DRGs of the animals
after SNL. There was a 5.9 fold decrease in the
number of CGRP—positive neurons in the ipsilateral
DRGs of the SNL animals (Student’s t-test t¼ 25.37,
df¼ 4, P< 0.0001). Treatment of SNL animals with
BT44 led to a significant increase in the number of IB4
expressing neurons in the ipsilateral DRGs (Kruskall–
Wallis test, H¼ 6.114, p¼ 0.0310). Post hoc analysis
with Dunn’s multiple comparison test revealed that the
12.5mg/kg dose of BT44 protected IB4-positive neurons
(P¼ 0.028) from SNL-induced lesion (Figure 7(a)). We
failed to detect statistically significant differences in the
number of CGRP-positive neurons in the ipsilateral
DRGs of the BT44-treated rats, although there was a
two-fold increase in the average numbers (Figure 7(c)).
The number of both CGRP- and IB-positive neurons in
the contralateral DRGs remained unchanged in response
to the treatment with BT44 (Figure 7(d) and (e)).
We quantified IB4- and CGRP-positive cells in the
DRGs of the diabetic animals in a pilot experiment
two and sixweeks post treatment with STZ (one section
per animal, three animals per group). We observed no
changes in cell counts between healthy and diabetic ani-
mals (data not shown) and, therefore, more extensive
analysis was not conducted.
Discussion
The novel RET agonist BT44 selectively activated
GFRa1/RET and GFRa3/RET receptors leading to
activation of intracellular MAPK/ERK signaling path-
way at concentrations 10 mM and 5mM, respectively. It
also increased levels of pRET and pERK in GFRa3/
RET expressing cells in concentrations 10 mM. BT44
(5–10 mM) stimulated neurite outgrowth from cultured
DRG neurons, alleviated established mechanical allody-
nia, and protected IB4-positive neurons in DRGs in a
rat SNL model of NP at the dose of 12.5mg/kg. In the
diabetic NP model, BT44 transiently reduced mechanical
hyperalgesia and cold allodynia after two weeks of treat-
ment at the dose of 5mg/kg.
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Compared with the parent compound BT13, BT44
had higher potency in immortalized cells and also in
the SNL model of NP. It is important to note that in
this study, we analyzed the effect of BT44 in animals
with established neuropathy, compared with the study
conducted with BT13 in which the compound was
administered to animals immediately after the surgery.25
As the methods of neurite outgrowth analysis were dif-
ferent for BT13 and BT44, direct comparisons of these
data are difficult. However, the efficacy of BT44 to pro-
mote neurite outgrowth was comparable to that of
ARTN. At the same time, another BT13 analogue, a
compound called BT18 in a similar assay to the one
used in this study, induced neurite outgrowth in a
smaller number of DRG neurons compared with
ARTN.27 BT44 activated luciferase reporter in immor-
talized cells controlled by GFRa1/RET and GFRa3/
RET, but not RET alone. BT44 increased also phos-
phorylation of RET and ERK in a dose-dependent
manner, irrespective of the presence of GFRa co-
receptor. Somewhat weaker ERK phosphorylation was
observed in response to BT44 in the cells lacking GFRa.
In silico studies identified a potential binding site for
compounds belonging to the BT scaffold on the interface
between RET and the GFRa co-receptor.46 Thus, the
presence of a co-receptor may change the conformation
of the complex and favor the activation of certain path-
ways in the cells providing a molecular basis for the
biased agonism. The discrepancy between ERK phos-
phorylation assay and luciferase assay data can also be
attributed to lower responsivity to stimulation of the
reporter cell line lacking GFRa. Taken together, these
data indicate that BT44 in contrast to BT13 can have
some degree of selectivity to GFRa/RET complex com-
pared with RET alone. This can be beneficial regarding
potential side-effects.
In the reporter gene and RET phosphorylation
assays, BT44 had higher potency compared with the
parent compound BT13, but lower potency and efficacy
than GFL proteins.25,26 This can have both positive and
negative implications in clinical use of RET agonists. On
one hand, it may be difficult to produce a sufficient level
of RET activation to elicit neurorestorative events in the
sensory system with low potency compounds. On the
other hand, high concentrations of GFLs produce unde-
sirable side effects in clinical trials and may result in
down regulation of receptors.21,22,47,48 Besides, in the
most recent trial in patients with neuropathic pain, a
low dose of ARTN produced the highest clinical
effect.48 While the treatment with GFLs21,22 and even
life-long moderate overexpression of natural ligands49
in the model organisms is generally well-tolerated,
RET is a proto-oncogene and its uncontrollable hyper-
activation may be detrimental. Therefore, the com-
pounds with moderate biological activity may be the
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Figure 6. The effect of BT44 in rats with diabetes mellitus.
Schemes of the STZ experiments are shown in panel (a). STZ was
injected on day 1. The black vertical lines indicate the days when
behavioral tests were performed. Rats received BT44 or vehicle
subcutaneously once daily every other day for two or six weeks
starting the day after the injection of STZ (day 0). Behavioral tests
were performed before the injection of STZ (BL), before the first
BT44 injection (day 0) and on weeks 1, 2, 3, 4, and 6. BT44
alleviates the mechanical hyperalgesia (b) and the cold allodynia
(c and d) in the STZ-treated animals. In (b), thresholds (g) to
mechanical stimulation are shown. Panel (c) shows cold allodynia
responses to acetone (positive responses/five trials), and panel (d)
shows the area under curve of the normalized values of d0–d14 in
the acetone test for each group. Data represent mean SEM. In
(b), **P< 0.01, ****P< 0.0001 (two-way ANOVA with Dunnett’s
multiple comparisons test; reference: the corresponding vehicle-
group without BT44 treatment). In (d), *P< 0.05, **** P< 0.0001
(Krustal–Wallis test with Dunn’s multiple comparison test).
n¼ 8–19. BL: baseline; VEH: vehicle; d: days; HC: healthy control;
DM: diabetes mellitus; AUC: area under curve.
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Figure 7. Expression of neuronal markers in DRGs of SNL animals treated with BT44. Representative images of IB4 and CGRP—probed
DRG sections (a). The number of marker-specific neurons in ipsilateral DRGs was calculated as a percentage of the total number of
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optimal strategy in the development of RET agonists for
therapeutic use.
BT44 selectively induced RET phosphorylation and
intracellular signaling as it influenced neither TrkA/B
phosphorylation nor levels of pERK in the cells express-
ing Trk receptors. A significant proportion of sensory
neurons expresses the TrkA receptor and its activation
stimulates nociception and hypersensitivity in vivo.50,51
Thus, inability of BT44 to activate TrkA and Trk-
dependent signaling is a beneficial trait since it reduces
the potential of the compound to produce pronocicep-
tive effects. BT44 (5 and 10 mM) also increased the
number of neurite-bearing DRG neurons in cultures,
indicative of its potential to restore sensory neurons.
BT44 attenuated mechanical hypersensitivity in the
surgery-induced animal model of neuropathic pain
(SNL) at the dose of 12.5mg/kg. Earlier, we showed
that the first direct RET agonist, BT13, delivered to
the animals right after the surgery, decreased mechanical
hypersensitivity in the rat SNL model of NP.25 Similar
attenuation of neuropathy is seen after ARTN and
GDNF administration.11,12 Importantly, here we admin-
istered BT44 two days post SNL when the animals had
already developed hypersensitivity and neuropathy.
Thus, for the first time, we were able to demonstrate
that a RET agonist can reverse established mechanical
allodynia, even though its effect is delayed and needs
several days to manifest.
A non-linear dose–response curve was observed in the
effect of BT44 on mechanical hypersensitivity. This phe-
nomenon is often observed with a growth factor-related
interventions in vitro.52 In addition, a non-linear dose–
response curve was seen in a clinical trial with ARTN
protein in neuropathic pain patients.48 These data are
difficult to explain. Potential reasons can include a
mechanistic and/or pharmacokinetic basis. The activa-
tion level of RET can decrease in the presence of high
doses of the ligand, because the receptor fails to dimerize
and signal when each monomer is bound to the co-
receptor/ligand complex53 or as a result of increased
phosphatase activity.54 We did not see a biphasic dose–
response in the biochemical assays, but in immortalized
cells, we overexpressed RET and GFRa3. Therefore, the
stoichiometry and availability of GFL receptor complex
components’ in immortalized cells and neurons may
differ. Alternatively, poor solubility of BT44 could
have resulted in the precipitation of the highest dose of
BT44 in animal experiments.
Differences in the effective dose of BT44 in vivo could
be explained by differences in the distinct pathophysio-
logical mechanisms of the NP animal models used.
Direct neuronal damage to the nerve in the SNL
model of NP induces rapid development of allodynia
and hyperalgesia12,15,41,43 which may need higher doses
of BT44 to recover than pain sensitivity changes in the
diabetic NP model. STZ selectively destroys pancreatic
b-cells and chronic hyperglycemia induces neuropathy
which may need a longer time to develop.42,55,56 This
could also explain why BT44 attenuated cold allodynia
in STZ animals but not in SNL animals. It should be
noted that in the STZ animals, the effect of BT44 was
seen on mechanical hyperalgesia which was assessed
with the paw pressure test. In contrast, in the SNL ani-
mals, the effect of BT44 was seen on mechanical allody-
nia which was assessed with the digital von Frey test. We
did not see the development of mechanical allodynia in
the STZ animals. BT44 did not have any effect on noci-
ceptive responses tested with the digital von Frey test in
the STZ animals or in healthy animals.
Similarly to ARTN,12,57 BT44 partially normalized
expression of the neuronal marker IB4 in rat DRGs in
vivo. We observed only a trend to an increase in the
number of CGRP-positive neurons in the DRGs of
SNL animals, although the average number of CGRP-
positive neurons was approximately two fold higher
after BT44 treatment. These data differ from the results
seen for ARTN12 and the first generation RET agonist
BT13,25 both of which protected CGRP-positive neu-
rons in rats with SNL. However, BT13 was delivered
to rats 1 h after SNL, while BT44 was administered two -
days post surgery. Importantly, in healthy animals, the
major population of sensory neurons expressing RET
are IB4-positive neurons, while among the CGRP-
positive neurons only 20% are also RET-positive.
Therefore, IB4-positive neurons represent a major
target for RET-specific compounds. RET agonists may
influence only a subset of CGRP-positive neurons pro-
ducing a small effect which is difficult to detect statisti-
cally. Indeed, BT44 seems to affect approximately 20%
of CGRP-positive neurons in average supporting the
proposed explanation.
Finally, the published data indicate that a nerve lesion
can alter the expression of RET and GFL co-receptors
in sensory neurons,11,25,58 but the time-dependence of
this alteration is not well established. Both ARTN and
BT13 were delivered soon after lesion, therefore, tran-
sient activation of RET expression can result in biolog-
ical effects of these compound in CGRP-positive
neurons. BT44 was injected two days after lesion when
RET expression in CGRP neurons can already be
diminished.
Here, we showed that BT44 attenuated mechanical
sensitivity and cold allodynia in the diabetes-induced
rat model of neuropathic pain. This is in line with a
previous study where topical application of the GDNF
signaling agonist, XIB4035, alleviated experimental dia-
betic neuropathy in rodents.24 It remains unclear wheth-
er BT44 can influence STZ-induced neuronal
degeneration in the diabetic model as the expression of
neuronal markers in the DRGs of the STZ-treated
Viisanen et al. 15
animals remained unchanged during the study. In con-
trast to the SNL model which is characterized by a quick
reduction in the expression of neuronal markers in
DRGs,12,15 neuronal degeneration in models of diabetic
neuropathy is slow.55,56 Unfortunately, we were not able
to monitor diabetic animals for longer periods, because
of ethical considerations. Importantly, BT44 did not
affect motor performance in the diabetic rats or mechan-
ical sensitivity in non-neuropathic rats indicating that its
antiallodynic and antihyperalgetic effects were specific
for neuropathy and not caused by sedation or impaired
coordination of the animals.
Interestingly, one of the GFL family members, pro-
tein NRTN, prevented the development of hyperglyce-
mia and protected pancreatic beta cells in the Zucker
diabetic fatty rats, but failed to influence sustained
hyperglycemia in these animals.59 BT44 did not influence
glucose levels in STZ animals, possibly because of the
administration schedule (after the lesion) and the aggres-
siveness of the STZ-induced degeneration of beta-cells.
It is of interest to assess the ability of BT44 to prevent
hyperglycemia and the development of hypersensitivity
in other models of diabetic neuropathy.
We showed that BT44 transiently attenuated cold
allodynia in a diabetes-induced rat model of neuropathic
pain at the dose of 5mg/kg. The lack of effect of BT44 to
cold allodynia in SNL animals can also be explained by
its selectivity to RET and inability to influence other
GFL receptors than RET.20
Although classification of sensory neurons to
CGRP- and IB4-positive is a crude division, it still
allows distinguishing of largely non-intersecting neuro-
nal populations. New sophisticated methods, such as
single cell sequencing,50 helped identify 11 distinct clas-
ses of DRG neurons mediating responses to different
types of stimuli. Interestingly, RET expression was
largely associated with mechanoreceptors, which is in
line with our behavioral data. Among other classes,
RET is expressed in so-called NP1-NP3 sensory neurons
which are likely to participate in pruritus and inflamma-
tory itch initiated signaling. This fact can be predictive of
side effects caused by RET-targeting treatments. Indeed,
in clinical trials with ARTN, pruritus was one of the
adverse effects associated with administration of this
protein.21,22,58
Since ARTN has induced cold allodynia and thermal
hyperalgesia in rodents,19,20 we assessed the effect of
BT44 on cold sensitivity also in healthy rats. Unlike
ARTN, BT44 did not increase sensitivity to cold stimuli,
which might be explained by the specificity of the small
molecule agonist to the RET receptor. The TRPM8-
positive neurons, which were negative for RET50 are
critical for the hyperalgesic effect of GFLs in response
to cold stimuli.20 Therefore, an altered response to cold
in GFL-treated animals is likely to be mediated by an
alternative receptor, for example, NCAM18,60 and
N-syndecan.16
Other major adverse effects of ARTN seen in clinical
trials include rash and thermal hypersensitivity.21,22,58 In
this study, BT44 failed to influence heat sensitivity in the
diabetes-induced rat model of NP and also cold sensitiv-
ity in healthy rats similar to our previous experiment in
healthy animals,25 in which a RET agonist failed to
influence thermal sensitivity. Thus, compounds selective-
ly targeting RET receptors might be free from this
liability.
Taken together, we discovered and characterized the
small molecule GFRa/RET agonist, BT44, the biologi-
cal effects of which are similar to those of ARTN and
GDNF, both in vitro and in vivo. It activates the GFL
receptor RET in cells, stimulates neurite outgrowth from
cultured DRG neurons, alleviates NP manifestations in
animal models, and reverts surgery-induced changes in
the expression of IB4 in DRG neurons in a rat model of
experimental neuropathy. In contrast to GFLs which
activate several receptors in neurons, BT44 and related
compounds seem to be selective to RET26 and to stimu-
late only RET-mediated processes. Therefore, it can
offer advantage for clinical translation compared with
GFLs by reducing the number of adverse effects.
Further modifications of BT44 aiming at improvement
of its pharmacological properties and biological activity
may eventually lead to the development of unique
disease-modifying drugs against NP, selectively targeting
the most important clinical problems namely mechanical
hyperalgesia and cold allodynia.
Acknowledgments
The authors are grateful to P€aivi Leinikka, Lahja Eurajoki,
Jenni Montonen, and Ilida Suleymanova for their excellent
assistance with the experimental procedures. The Nuclear
Magnetic Resonance facility at the Institute of
Biotechnology, University of Helsinki supported by Biocenter
Finland and Helsinki Institute of Life Science (HiLIFE) is
acknowledged for verification of BT44 structure.
Author Contributions
HV, OK, MK, PR, EK, and YAS designed the study; MK
designed BT44; HV, UN, OK, AKM, VJ, and TL performed
experiments; HV, UN, OK, AKM, VJ, TL, PR, EK, and YS
analyzed and interpreted data; HV and YAS drafted the man-
uscript; all authors contributed to the writing of the manuscript
and approved its final version; YAS conceived the study.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of
interest with respect to the research, authorship, and/or publi-
cation of this article: MK is an inventor in composition of
matter patents of BT compounds (US Patent, No 8,901,129
B2 and European Patent, No 2509953) and in a patent
16 Molecular Pain
application WO 2014041179 A1 on the treatment of peripheral
neuropathy using GFRa3 type receptor agonists.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: This study was supported by funding from the
European Union Seventh Framework Programme (FP7/
2007–2013) under grant agreement no 602919, Finnish
Medical Society (Finska L€akares€allskapet), University of
Helsinki 375th Anniversary Grant, the Academy of Finland
(grants 1315043 and 1325555), GeneCode Ltd, Centre of
Excellence in Molecular Cell Engineering, Estonia, 2014–
2020.4.01.15–013, and grant PUT582 from the Estonian
Research Council.
ORCID iD
Yulia A Sidorova https://orcid.org/0000-0001-8230-0530
Supplemental Material
Supplemental material for this article is available online.
References
1. Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett
MI, Benoliel R, Cohen M, Cruccu G, Davis KD, Evers S,
First M, Giamberardino MA, Hansson P, Kaasa S,
Korwisi B, Kosek E, Lavandʼhomme P, Nicholas M,
Nurmikko T, Perrot S, Raja SN, Rice ASC, Rowbotham
MC, Schug S, Simpson DM, Smith BH, Svensson P,
Vlaeyen JWS, Wang S-J, Barke A, Rief W, Treede R-D;
Classification Committee of the Neuropathic Pain Special
Interest Group (NeuPSIG). The IASP classification of
chronic pain for ICD-11: chronic neuropathic pain. Pain
2019; 160: 53–59.
2. Yawn BP, Wollan PC, Weingarten TN, Watson JC,
Hooten WM, Melton LJ. The prevalence of neuropathic
pain: clinical evaluation compared with screening tools in a
community population. Pain Med 2009; 10: 586–593.
3. Smith BH, Torrance N. Epidemiology of neuropathic pain
and its impact on quality of life. Curr Pain Headache Rep
2012; 16: 191–198.
4. Haanp€a€a ML, Treede R-D. Diagnosis and classification of
neuropathic pain. PainClinical Updat 2010; 18: 1–6.
5. Scadding J, Koltzenburg M. Painful peripheral neuropa-
thies. In: McMahon S, Koltzenburg M (eds) Wall
Melzack’s textbook of pain. 5th ed. London: Elsevier,
2006, pp. 973–999.
6. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG,
Selvarajah D, Orengo C, Tesfaye S, Rice ASC, Bennett
DLH. The Pain in Neuropathy Study (PiNS): a
cross-sectional observational study determining the
somatosensory phenotype of painful and painless diabetic
neuropathy. Pain 2016; 157: 1132–1145.
7. Attal N; Neuropathic Pain Special Interest Group of the
International Association for the Study of Pain.
Management of neuropathic cancer pain. Ann Oncol
2010; 21: 1134–1135.
8. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin
MJ, Backonja M, Betts RF, Gershon AA, Haanp€a€a ML,
McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman
MN, Langston DP, Petersen KL, Rowbotham MC,
Schmader KE, Stacey BR, Tyring SK, Wijck AJMv,
Wallace MS, Wassilew SW, Whitley RJ.
Recommendations for the management of herpes zoster.
Clin Infect Dis 2007; 44: S1–S26.
9. Cherry CL, Wadley AL, Kamerman PR. Diagnosing and
treating HIV-associated sensory neuropathy: a global per-
spective. Pain Manag 2016; 6: 191–199.
10. Finnerup NB, Attal N, Haroutounian S, McNicol E,
Baron R, Dworkin RH, Gilron I, Haanp€a€a M, Hansson
P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN,
Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH,
Wallace M. Pharmacotherapy for neuropathic pain in
adults: a systematic review and meta-analysis. Lancet
Neurol 2015; 14: 162–173.
11. Boucher TJ, Okuse K, Bennett DLH, Munson JB, Wood
JN, McMahon SB. Potent analgesic effects of GDNF in
neuropathic pain states. Science 2000; 290: 124–127.
12. Gardell LR, Wang R, Ehrenfels C, Ossipov MH,
Rossomando AJ, Miller S, Buckley C, Cai AK, Tse A,
Foley SF, Gong B, Walus L, Carmillo P, Worley D,
Huang C, Engber T, Pepinsky B, Cate RL, Vanderah
TW, Lai J, Sah DWY, Porreca F. Multiple actions of sys-
temic artemin in experimental neuropathy. Nat Med 2003;
9: 1383–1389.
13. Takasu K, Sakai A, Hanawa H, Shimada T, Suzuki H.
Overexpression of GDNF in the uninjured DRG exerts
analgesic effects on neuropathic pain following segmental
spinal nerve ligation in mice. J Pain 2011; 12: 1130–1139.
14. Harvey P, Gong B, Rossomando AJ, Frank E.
Topographically specific regeneration of sensory axons in
the spinal cord. Proc Natl Acad Sci USA 2010; 107:
11585–11590.
15. Wang R, Rossomando A, Sah DWY, Ossipov MH, King
T, Porreca F. Artemin induced functional recovery and
reinnervation after partial nerve injury. Pain 2014; 155:
476–484.
16. Bespalov MM, Sidorova YA, Tumova S, Ahonen-Bishopp
A, Magalh~aes AC, Kulesskiy E, Paveliev M, Rivera C,
Rauvala H, Saarma M. Heparan sulfate proteoglycan
syndecan-3 is a novel receptor for GDNF, neurturin, and
artemin. J Cell Biol 2011; 192: 153–169.
17. Bespalov MM, Saarma M. GDNF family receptor com-
plexes are emerging drug targets. Trends Pharmacol Sci
2007; 28: 68–74.
18. Paratcha G, Ledda F, Iba´~nez CF. The neural cell adhesion
molecule NCAM is an alternative signaling receptor for
GDNF family ligands. Cell 2003; 113: 867–879.
19. Elitt CM, McIlwrath SL, Lawson JJ, Malin SA, Molliver
DC, Cornuet PK, Koerber HR, Davis BM, Albers KM.
Artemin overexpression in skin enhances expression of
TRPV1 and TRPA1 in cutaneous sensory neurons and
leads to behavioral sensitivity to heat and cold.
J Neurosci 2006; 26: 8578–8587.
Viisanen et al. 17
20. Lippoldt EK, Elmes RR, McCoy DD, Knowlton WM,
McKemy DD. Artemin, a glial cell line-derived neurotro-
phic factor family member, induces TRPM8-dependent
cold pain. J Neurosci 2013; 33: 12543–12552.
21. Okkerse P, Hay JL, Versage E, Tang Y, Galluppi G,
Ravina B, Verma A, Williams L, Aycardi E, Groeneveld
GJ. Pharmacokinetics and pharmacodynamics of multiple
doses of BG00010, a neurotrophic factor with anti-
hyperalgesic effects, in patients with sciatica. Br J Clin
Pharmacol 2016; 82: 108–117.
22. Rolan PE, O’Neill G, Versage E, Rana J, Tang Y,
Galluppi G, Aycardi E. First-in-human, double-blind, pla-
cebo-controlled, randomized, dose-escalation study of
BG00010, a glial cell line-derived neurotrophic factor
family member, in subjects with unilateral sciatica. PLoS
One 2015; 10: e0125034.
23. Tokugawa K, Yamamoto K, Nishiguchi M, Sekine T,
Sakai M, Ueki T, Chaki S, Okuyama S. XIB4035, a
novel nonpeptidyl small molecule agonist for GFRalpha-
1. Neurochem Int 2003; 42: 81–86.
24. Hedstrom KL, Murtie JC, Albers K, Calcutt Na, Corfas
G. Treating small fiber neuropathy by topical application
of a small molecule modulator of ligand-induced GFRa/
RET receptor signaling. Proc Natl Acad Sci USA 2014;
111: 2325–2330.
25. Sidorova YA, Bespalov MM, Wong AW, Kambur O,
Jokinen V, Lilius TO, Suleymanova I, Karelson G,
Rauhala PV, Karelson M, Osborne PB. A novel small mol-
ecule GDNF receptor RET agonist, BT13, promotes neu-
rite growth from sensory neurons in vitro and attenuates
experimental neuropathy in the rat. Front Parmacol 2017;
8: 1–18.
26. Mahato AK, Kopra J, Renko J-M, Visnapuu T, Korhonen
I, Pulkkinen N, Bespalov MM, Domanskyi A, Ronken E,
Piepponen TP, Voutilainen MH, Tuominen RK, Karelson
M, Sidorova YA, Saarma M. Glial cell line–derived neuro-
trophic factor receptor rearranged during transfection ago-
nist supports dopamine neurons in vitro and enhances
dopamine release in vivo. Mov Disord 2020; 35: 245–255.
27. Bespalov MM, Sidorova YA, Suleymanova I, Thompson
J, Kambur O, Jokinen V, Lilius T, Karelson G, Puusepp L,
Rauhala P, Kalso E. Novel agonist of GDNF family
ligand receptor RET for the treatment of experimental
neuropathy. BioRxiv 2016; : 061820.
28. Saarma M, Karelson M, Pilv M, Bespalov MM. Methods
of facilitating neural cell survival using GDNF family
ligand (GFL) mimetics or RET signalling pathway activa-
tors. European Patent, No 2509953, US Patent No
8901129B2. USA, Europe: United States Patent and
Trademark Office, 2014.
29. Wang X, Baloh RH, Milbrandt J, Garcia KC. Structure of
artemin complexed with its receptor GFRa3: convergent
recognition of glial cell line-derived neurotrophic factors.
Structure 2006; 14: 1083–1092.
30. Parkash V, Lepp€anen V-M, Virtanen H, Jurvansuu JM,
Bespalov MM, Sidorova YA, Runeberg-Roos P, Saarma
M, Goldman A. The structure of the glial cell line-derived
neurotrophic factor-coreceptor complex: insights into RET
signaling and heparin binding. J Biol Chem 2008; 283:
35164–35172.
31. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart
WE, Belew RK, Olson AJ. Automated docking using a
Lamarckian genetic algorithm and an empirical binding
free energy function. J Comput Chem 1998; 19: 1639–1662.
32. Karelson M, Dobchev DA, Karelson G, Tamm T, T€amm
K, Nikonov A, Mutso M, Merits A. Fragment-based
development of HCV protease inhibitors for the treatment
of hepatitis C. Curr Comput Aided Drug Des 2012; 8:
55–61.
33. Sidorova YA, M€atlik K, Paveliev M, Lindahl M, Piranen
E, Milbrandt J, Arum€ae U, Saarma M, Bespalov MM.
Persephin signaling through GFRa1: the potential for the
treatment of Parkinson’s disease. Mol Cell Neurosci 2010;
44: 223–232.
34. Eketj€all S, Fainzilber M, Murray-Rust J, Iba´~nez CF.
Distinct structural elements in GDNF mediate binding to
GFRa1 and activation of the GFRa1-c-RET receptor
complex. Embo J 1999; 18: 5901–5910.
35. Lepp€anen V-M, Bespalov MM, Runeberg-Roos P,
Puurand U, Merits A, Saarma M, Goldman A. The struc-
ture of GFRa1 domain 3 reveals new insights into GDNF
binding and RET activation. Embo J 2004; 23: 1452–1462.
36. Paveliev M, Airaksinen MS, Saarma M. GDNF family
ligands activate multiple events during axonal growth in
mature sensory neurons. Mol Cell Neurosci 2004; 25:
453–459.
37. Zimmermann M. Ethical guidelines for investigations of
experimental pain in conscious animals. Pain 1983;
109–110.
38. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman
DG. Improving bioscience research reporting: the
ARRIVE guidelines for reporting animal research.
Osteoarthr Cartil 2012; 20: 256–260.
39. McGrath JC, Drummond GB, McLachlan EM, Kilkenny
C, Wainwright CL. Editorial: guidelines for reporting
experiments involving animals: the ARRIVE guidelines.
Br J Pharmacol 2010; 160: 1573–1576.
40. Knopp KL, Stenfors C, Baastrup C, Bannon AW, Calvo
M, Caspani O, Currie G, Finnerup NB, Huang W,
Kennedy JD, Lefevre I, Machin I, Macleod M, Rees H,
Rice ASC, Rutten K, Segerdahl M, Serra J, Wodarski R,
Berge O-G, Treede R-D. Experimental design and
reporting standards for improving the internal validity
of pre-clinical studies in the field of pain: consensus
of the IMI-European consortium. Scand J Pain 2015; 7:
58–70.
41. Kim SH, Chung JM. An experimental model for peripher-
al neuropathy produced by segmental spinal nerve ligation
in the rat. Pain 1992; 50: 355–363.
42. Courteix C, Eschalier A, Lavarenne J. Streptozocin-
induced diabetic rats: behavioural evidence for a model
of chronic pain. Pain 1993; 53: 81–88.
43. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM.
Behavioral signs of ongoing pain and cold allodynia in a
rat model of neuropathic pain. Pain 1994; 59: 369–376.
44. Lew M. Good statistical practice in pharmacology prob-
lem 2. Br J Pharmacol 2007; 152: 299–303.
18 Molecular Pain
45. Lew M. Good statistical practice in pharmacology prob-
lem 1. Br J Pharmacol 2007; 152: 295–298.
46. Ivanova L, Tammiku-Taul J, Garcıa-Sosa AT, Sidorova
Y, Saarma M, Karelson M. Molecular dynamics simula-
tions of the interactions between glial cell line-derived neu-
rotrophic factor family receptor GFRa1 and small-
molecule ligands. ACS Omega 2018; 3: 11407–11414.
47. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE,
Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M,
Wooten GF; ICV GDNF Study Group. Randomized,
double-blind trial of glial cell line-derived neurotrophic
factor (GDNF) in PD. Neurology 2003; 60: 69–73.
48. Backonja M, Williams L, Miao X, Katz N, Chen C. Safety
and efficacy of neublastin in painful lumbosacral radicul-
opathy. Pain 2017; 158: 1802–1812.
49. Turconi G, Kopra J, V~oikar V, Kulesskaya N, Vilenius C,
Piepponen TP, Andressoo J-O. Molecular therapy – meth-
ods & clinical development chronic two-fold elevation of
endogenous GDNF levels is safe and enhances motor and
dopaminergic function in aged mice. Mol Ther Methods
Clin Dev 2020; 17: 831–842.
50. Usoskin D, Furlan A, Islam S, Abdo H, L€onnerberg P,
Lou D, Hjerling-Leffler J, Haeggstr€om J, Kharchenko O,
Kharchenko PV, Linnarsson S, Ernfors P. Unbiased clas-
sification of sensory neuron types by large-scale single-cell
RNA sequencing. Nat Neurosci 2015; 18: 145–153.
51. Hirose M, Kuroda Y, Murata E. NGF/TrkA signaling as a
therapeutic target for pain. Pain Pract 2016; 16: 175–182.
52. Hou J-GG, Lin L-FH, Mytilineou C. Glial cell line-derived
neurotrophic factor exerts neurotrophic effects on dopami-
nergic neurons in vitro and promotes their survival and
regrowth after damage by 1-methyl-4-phenylpyridinium.
J Neurochem 1996; 66: 74–82.
53. Schlee S, Carmillo P, Whitty A. Quantitative analysis
of the activation mechanism of the multicomponent
growth-factor receptor Ret. Nat Chem Biol 2006; 2:
636–644.
54. Yadav L, Pietil€a E, €Ohman T, Liu X, Mahato AK,
Sidorova Y, Lehti K, Saarma M, Varjosalo M. PTPRA
phosphatase regulates GDNF-dependent RET signaling
and inhibits the RET mutant MEN2A oncogenic poten-
tial. iScience 2020; 23: 100871.
55. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve
fiber quantification in the assessment of diabetic neuropa-
thy. Acta Histochem 2008; 110: 351–362.
56. Gao F, Zheng ZM. Animal models of diabetic neuropathic
pain. Exp Clin Endocrinol Diabetes 2014; 122: 100–106.
57. Han X, Zhu S, Wang B, Chen L, Li R, Yao W, Qu Z.
Antioxidant action of 7,8-dihydroxyflavone protects PC12
cells against 6-hydroxydopamine-induced cytotoxicity.
Neurochem Int 2014; 64: 18–23.
58. Bennett DL, Michael GJ, Ramachandran N, Munson JB,
Averill S, Yan Q, McMahon SB, Priestley JV. A distinct
subgroup of small DRG cells express GDNF receptor
components and GDNF is protective for these neurons
after nerve injury. J Neurosci 1998; 18: 3059–3072.
59. Trevaskis JL, Sacramento CB, Jouihan H, Ali S, Le Lay J,
Oldham S, Bhagroo N, Boland BB, Cann J, Chang Y,
O’Day T, Howard V, Reers C, Winzell MS, Smith DM,
Feigh M, Barkholt P, Schreiter K, Austen M, Andag U,
Thompson S, Jermutus L, Coghlan MP, Grimsby J,
Dohrmann C, Rhodes CJ, Rondinone CM, Sharma A.
Neurturin and a GLP-1 analogue act synergistically to alle-
viate diabetes in Zucker diabetic fatty rats. Diabetes 2017;
66: 2007–2018.
60. Ilieva M, Nielsen J, Korshunova I, Gotfryd K, Bock E,
Pankratova S. Artemin and an artemin-derived peptide,
artefin, induce neuronal survival, and differentiation
through RET and NCAM. Front Mol Neurosci 2019; 12:
1–14.
Viisanen et al. 19
